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Abstract
Objective: To alert the pediatrician who is following up HIV-infected patients about the 
possibility of non-cirrhotic portal hypertension (NCPH) in this period of life, in order to 
avoid the catastrophic consequences of this disease as bleeding esophageal varices.
Case description: A 13 years old HIV-infected patient by vertical route was receiving dida-
nosine (ddI) for 12 years. Although the HIV viral load had been undetectable for 12 years, 
this patient showed gradual decrease of CD4+ T cells, prolonged thrombocytopenia and 
high alkaline phosphatase. Physical examination detected splenomegaly, which triggered 
the investigation that led to the diagnosis of severe liver fibrosis by transient elastogra-
phy, probably due to hepatic toxicity by prolonged use of ddI.
Comments: This is the first case of NCPH in HIV-infected adolescent described in Brazil. 
Although, the NCPH is a rare disease entity in seropositive patients in the pediatric 
age group, it should be investigated in patients on long-term ddI or presenting clinical 
and laboratories indicators of portal hypertension, as splenomegaly, thrombocytopenia 
and increased alkaline phosphatase.
© 2015 Sociedade de Pediatria de São Paulo. Published by Elsevier Editora Ltda. All rights 
reserved.
DOI of original article: http://dx.doi.org/10.1016/j.rpped.2014.09.001 
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Hipertensão portal não cirrótica em adolescente infectado pelo vírus da imunodefi-
ciência humana (HIV)
Resumo
Objetivo: Alertar o pediatra sobre a ocorrência de hipertensão portal não cirrótica 
(HPNC) na faixa etária pediátrica, no sentido de evitar as consequências catastróficas 
dessa doença, como o sangramento de varizes de esôfago.
Descrição do caso: Paciente de 13 anos, infectado pelo HIV por via vertical, recebia es-
quema antirretroviral com didanosina (ddI) havia 12 anos. Apesar do controle adequado 
da replicação viral, com carga viral do HIV indetectável havia 12 anos, passou a apresen-
tar diminuição gradativa dos linfócitos TCD4+, trombocitopenia prolongada e fosfatase 
alcalina elevada. O exame físico detectou esplenomegalia, que desencadeou o processo 
de investigação e culminou no diagnóstico de fibrose hepática acentuada pela elastogra-
fia, por provável toxicidade hepática devido ao uso prolongado de ddI.
Comentários: Este é o primeiro caso de HPNC em adolescente infectado pelo HIV descrito 
no Brasil. Embora seja entidade mórbida rara em pacientes soropositivos para o HIV na 
faixa etária pediátrica, deve ser investigada nos pacientes em uso prolongado de ddI 
ou que apresentem indicadores clínicos e/ou laboratoriais de hipertensão portal, como 
esplenomegalia, trombocitopenia e aumento de fosfatase alcalina.
© 2015 Sociedade de Pediatria de São Paulo. Publicado por Elsevier Editora Ltda. Todos os 
direitos reservados.
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Introduction
It is estimated that approximately 718,000 individuals live 
with HIV/AIDS in Brazil, representing a prevalence rate of 
0.4% in the general population. AIDS detection rate in Brazil 
has increased about 2% in the last 10 years, especially 
among young individuals aged 15-24 years and adults aged 
50 years or older. However, AIDS detection rate in children 
younger than five years old, an indicator used in Brazil to 
monitor HIV vertical transmission, decreased by 35.8% com-
pared to 2003.1 The combined antiretroviral therapy (cART) 
resulted in a sharp decrease in mortality of children and 
adolescents infected with HIV.2 Nucleoside analogue reverse 
transcriptase inhibitors (NRTIs) were the first available 
antiretroviral drugs and it is not rare to find HIV-infected 
patients that have been using these drugs (alone or com-
bined with other antiretroviral classes) for over 10 years.
Infectious diseases (including opportunistic infections) 
progressively decreased with treatment, but the non-infec-
tious complications, including liver disease, have become 
significant causes of morbidity and mortality in the long-
term among survivors. A retrospective study in South 
America (Brazil, Mexico, Argentina and Peru), including 
6,000 HIV-positive adult patients, showed that terminal 
liver failure or cirrhosis was the leading cause of death, 
with 54/130 (42%) confirmed or probable cases based on 
clinical, laboratory or histological findings.3 Rubio et al., in 
2009, used non-invasive procedures to assess hepatic 
involvement in 26 children chronically infected with HIV 
through vertical route and found that more than 60% of the 
population had signs of liver disorder in at least one of the 
tests.4
Non-cirrhotic Portal Hypertension (NCPH) is one of the 
clinical entities that affect HIV-infected patients. It is a 
rare disease, occurring in up to 0.5% of HIV-positive adult 
patients.5 The direct action of HIV itself, endothelial and 
mitochondrial damage, hypercoagulability and microbial 
translocation are factors possibly implicated in its patho-
genesis.6-8 The aim of this case report is to alert pediatri-
cians about the occurrence of non-cirrhotic portal hyper-
tension (NCPH) in pediatric patients, in order to avoid the 
catastrophic consequences of this disease such as bleeding 
of esophageal varices.
Case description
This case report was approved by the Institutional Review 
Board of UNIFESP (N. CAAE: 31701414.8.0000.5505) and 
informed consent forms were signed by patients and their 
legal guardians.
A preterm male infant, born by cesarean section, with 
1,250 g birth weight, 36 cm height and Apgar scores at 1 
and 5 minutes of six and eight, was infected by the human 
immunodeficiency virus (HIV) through vertical transmis-
sion. The mother was a user of illicit drugs with irregular 
use of zidovudine (AZT) during pregnancy and received 
intrapartum prophylaxis. The child was adopted at 6 months 
of life. In December 2001 (7 months old) he started fol-
low-up of HIV infection at the Outpatient Clinic of the 
Discipline of Pediatric Infectious Diseases, UNIFESP/EPM 
(CEADIPE), with HIV viral load of 1,100,000 copies/mL and 
CD4+ lymphocytes of 819 cells/mm3 (24.1%). He was classi-
fied as B2, and was treated with cART (Zidovudine-AZT + 
didanosine-ddI + Nelfinavir-NFV).
There was good adherence to antiretroviral therapy 
leading to control of viral replication (undetectable HIV 
viral load) and normalization of CD4+ T lymphocyte values. 
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The patient had a history of two hospitalizations at the 
beginning of follow-up (acute otitis media and pneumonia 
at 8 months of age and diarrhea two months later), and 
some uncomplicated clinical conditions, such as chicken 
pox and scarlet fever during the clinical follow-up. He 
received the full vaccination schedule recommended for 
HIV-infected children. cART was maintained until June 
2007, when NFV was no longer available, being replaced by 
Nevirapine (AZT+ddI+nevirapine-NVP). There was control of 
viral replication and absence of immunosuppression (nor-
mal CD4+ levels), with appropriate physical and neurologi-
cal development, without disease complications or clinical 
complaints until April 2009, when he started to present 
with thrombocytopenia (<150,000 platelets/microliter), 
without bleeding episodes. In March 2013 he started to 
show immunosuppression (decrease in CD4+ T lymphocyte 
levels <500 cells/mm3).
In August 2013, aged 13 years, he was clinically stable, 
weighed 35.6kg, with a body mass index of 14.8 (between 
the 3rd and the15th percentiles); 155.5cm tall; H/A=111% 
(>97th percentile); blood pressure 99×75mmHg; rare poste-
rior inguinal and cervical ganglia (<0.5cm diameter), palpa-
ble liver at 3.5cm from the right costal margin and spleen 
at 6.0cm from the left costal margin (smooth surface, pain-
less). Tanner pubertal stage was G3P3 and neurological 
examination was normal.
Infectious and oncological causes were investigated and 
ruled out for the immunosuppression and hepatospleno-
megaly: immunity for CMV, hepatitis A and hepatitis B, neg-
ative serology for hepatitis C, toxoplasmosis and mononu-
cleosis. The abdominal ultrasound confirmed splenomega-
ly; CT of the chest and abdomen showed normal chest, 
homogeneous hepatosplenomegaly, compressing the kid-
neys posteriorly, and increased portal vein dimensions 
(1.8 cm) (Fig. 1).
The myelogram without anomalous cells in the bone 
marrow disclosed a G/E ratio of 0.9/1; marked erythrocyte 
hyperplasia with preserved maturation; mild signs of 
dyserythropoiesis; granulocytic normoplasia with preserved 
maturation, as well as the presence of mild megaloblasto-
sis; lymphocyte normoplasia and presence of plasmocytes; 
monocyte normoplasia, increased number of macrophages 
and megakaryocytic normoplasia.
The CBC showed hemoglobin (Hb) of 13.1g/dL; 
Hematocrit (Htc) of 40.4%, platelets of 63,000/uL, leuko-
cytes 3,700/uL (7% band cells, 64% neutrophils, 1% eosin-
ophils, 23% lymphocytes, 5% monocytes). Other tests: 
C-reactive protein (CRP) 0.45mg/L, lactate dehydroge-
nase (LDH) 163 U/L, aspartate aminotransferase (AST) 
40U/L, alanine aminotransferase (ALT) 36U/L, gamma-glu-
tamyl transferase (gammaGT) 68U/L, alkaline phospha-
tase (AP) 382U/L, total protein 7.4g/dL, albumin 4.26g/
dL. APRI index of 1.11 (aspartate aminotransferase-plate-
lets ratio index).
Considering these laboratory tests, a hypothesis of portal 
hypertension due to liver toxicity caused by didanosine 
(ddI) was suggested. The cART was modified, with ddI with-
drawal and substitution of the previous regimen (Abacavir-
ABC+ Lamivudine-3TC+ Lopinavir and Ritonavir-LPV/r); 
liver elastography and upper digestive endoscopy were 
requested. The liver elastography showed no steatosis, E 
index of 10.0kPa with marked hepatic fibrosis (F2-F3 of 
Metavir). The endoscopy disclosed small-caliber esophageal 
varices, intense portal hypertensive gastropathy and gas-
tric polyps.
Discussion
Only two other cases of non-cirrhotic portal hypertension 
(NCPH) have been previously described in children and ado-
lescents infected with HIV: a 10-year-old in Italy9 and a 
15-year-old in the United States,10 both with prolonged 
exposure to ddI and history of esophageal variceal bleed-
ing. No other cases were identified in Brazil. The investiga-
tion of this case was triggered because the patient had 
control of HIV viral replication (undetectable HIV viral load 
for 12 years), had been using cART with ddI for 12 years 
without clinical symptoms, had thrombocytopenia, pro-
gressive decrease in CD4+ T cell levels and hepatospleno-
megaly.
In addition to co-infections by hepatitis B and C virus, 
the infection of liver cells by HIV may contribute to the 
progression of liver disease by direct and indirect mecha-
nisms.11 The HIV can directly infect hepatocytes, hepatic 
stellate cells (HSCs) and Kupffer cells. The glycoprotein 120 
(gp120) of the HIV bound to the CXCR4 correceptor can 
induce apoptosis of hepatocytes and activation of HSCs, 
both contributing to the formation of liver fibrosis.11 
Indirectly, the nucleoside analog reverse transcriptase 
inhibitors and the HIV itself (effect via peroxisome prolifer-
ator-activated receptor - PPAR) can contribute to liver dis-
ease by inducing metabolic syndrome. Gastrointestinal 
tract infection by HIV leads to lipopolysaccharide (LPS) 
increase, which can stimulate the three types of liver cells 
to produce proinflammatory cytokines and chemokines that 
attract activated lymphocytes and monocytes to the liver, 
further increasing fibrosis.11
One of the clinical presentations of liver disease in HIV 
mono-infected patient is the non-cirrhotic portal hyperten-
sion (NCPH), first described in adults by Maida et al.12 
Figure 1 Abdominal computed tomography, showing 
homogeneous hepatosplenomegaly, exerting posterior 
compression on the kidneys. São Paulo, SP, Brazil, 2014. The 
arrows indicate the compression of the kidneys bilaterally by 
hepatomegaly (R) and splenomegaly (L).
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Parikh et al.,13 in 2014, studying HIV-infected adults with 
NCPH found that most of them had splenomegaly, thrombo-
cytopenia and elevated alkaline phosphatase. Maida et al., 
in 2006, assessed a group of 17 HIV-infected adults with 
cryptogenic liver disease, and comparing them to a control 
group (HIV-infected patients without liver disease), found 
prolonged use of ddI as the only independent factor associ-
ated with the development of NCPH.12 The same was 
observed by Schouten et al.14 in 2012, demonstrating that 
the risk factors for the development of NCPH were: long-
term exposure (11 years) to ddI alone and/or short-term 
exposure (4 years) to ddI+ Stavudine-D4T or ddI+Tenofo-
vir-TDF combination.
The antiretroviral agents didanosine (ddI), stavudine 
(d4T) and zalcitabine are stronger inhibitors of mitochon-
drial DNA polymerase than Zidovudine (AZT), Lamivudine 
(3TC) and Abacavir (ABC), and cause increased mitochon-
drial toxicity. Drug-induced depletion of mitochondrial DNA 
polymerase is an assumed underlying mechanism of lactic 
acidosis associated with steatosis, steatohepatitis and liver 
failure in HIV-infected individuals. The association between 
mitochondrial hepatotoxicity and NCPH was also suggested 
by Schouten et al. in 2012.14
More recently, Parikh et al., in 2014,13 based on the 
prevalence of significant factors in patients with NCPH 
when compared with the control group, proposed a flow 
chart to assess this diagnosis: exposure to ddI or spleno-
megaly in an HIV-positive patient without known liver dis-
ease should trigger an evaluation for NCPH (excluding 
patients with a history of alcohol consumption and viral 
hepatitis detected by serological screening). In the pres-
ence of thrombocytopenia, AST>40U/L or AP>115U/L, the 
patient should be referred to a hepatologist and start the 
investigation.13
Considering that liver involvement can occur for a long 
period of time before the clinical manifestations of liver 
disease become evident, and that children infected with 
HIV by vertical transmission are surviving for longer periods 
with continuous use of antiretroviral drugs, it is necessary 
to seek markers capable of identifying liver damage as 
early as possible.
Siberry et al., in 201415 evaluated the APRI (aspartate 
aminotransferase/platelet ratio) index as a predictor of 
liver fibrosis in a cohort of HIV-infected children by vertical 
transmission in Latin America. The cutoff value for this 
index in children has not been established, but an index 
>1.5 seem to be quite specific, although it lacks sensitivi-
ty.15 The studied patient had an APRI of 1.11 at the start of 
the investigation of hepatosplenomegaly, but this index 
increased to 2.0 after one month.
The NCPH results in bleeding of esophageal varices. In 
the study by Parikh et al.,13 of 34 cases with NCPH, 55.9% 
had bleeding, demonstrating that NCPH is underdiagnosed, 
perhaps due to lack of an algorithm for the investigation. 
Esophageal varices were identified in almost 90% of the 
group with NCPH in this study, a higher prevalence than 
that found by other researchers: 15% in the study by Mallet 
et al.,5 in 2007, and 69% in the study by Maida et al.,6 in 
2008. The patient we described had small-caliber esopha-
geal varices, without bleeding. The substitution of ddI by 
another antiretroviral agent in this case aimed to stop the 
progression of liver fibrosis, decreasing the risk of disease 
complications.
The purpose of this clinical case report is to alert the 
professionals that treat individuals infected with HIV/AIDS, 
particularly pediatricians, about the possibility of NCPH in 
children and adolescents infected with HIV through vertical 
transmission submitted to long-term use of cART. One 
should consider as warning signs the presence of thrombo-
cytopenia and hepatosplenomegaly, regardless of elevated 
liver enzymes. Liver fibrosis should be investigated in these 
patients and early identification of the disease can prevent 
its severe consequences, such as bleeding of esophageal 
varices.
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